Mylan MYL

  1. All
  2. Commentary
  3. Stock Reports
  4. ETF Reports
  5. Headlines
    1. Mylan files ANDA for generic Copaxone

      Headlines

      Thu, 28 Aug 2014

      The FDA accepts Mylan 's ( MYL -0.2% ) ANDA for a 3x/week Glatiramer Acetate Injection 40 mg ..... for the treatment of patients with relapsing multiple sclerosis. Mylan believes it is one of the first companies to make the filing so it

    2. Mylan : Deeply Undervalued On Unwarranted Approval Concerns

      Headlines

      Wed, 27 Aug 2014

      By William Meyers : Mylan (NASDAQ: MYL ) is a manufacturer of generic pharmaceuticals ..... 30. I expect by the end of 2015 Mylan will have doubled to about $100 ..... between now and the end of 2015. Mylan has spent the last few years setting

    3. Apricus Biosciences: A Screaming Buy Or A Falling Knife?

      Headlines

      Mon, 25 Aug 2014

      the company has softened its message about the Canadian launch due to company selling its non-US assets to Mylan , Inc (NASDAQ: MYL ): With respect to the launch of Vitaros in Canada, we continue to support Abbott's efforts to enhance the

    4. New Morningstar Analyst Report for Abbott Laboratories

      Stock Reports

      Mon, 25 Aug 2014

      bottom-line growth more quickly than top-line growth.Abbott's sale of it established pharma business in developed markets to Mylan and its acquisition of CFR and Veropharm have put Abbott's branded generics business in a strong position to benefit from

    5. Mylan launches generic version of Klor-Con

      Headlines

      Fri, 22 Aug 2014

      Mylan (NASDAQ: MYL ) begins shipping its potassium chloride extended release tablets (8 mEq (600 mg) and 10 mEq (750 mg)), generic versions

    6. Not so fast, Mylan

      Headlines

      Wed, 20 Aug 2014

      0.3% ) intervened on Hospira's behalf because the ruling would deprive it of the six-month exclusivity it negotiated in its patent infringement settlement with Hospira in December. Related ticker: ( MYL +2.8% ) Post your comment!

    7. Mylan launches generic version of Precedex

      Headlines

      Tue, 19 Aug 2014

      After the FDA approved its ANDA yesterday, Mylan ( MYL +1.3% ) launches dexmedetomidine hydrochoride injection ..... 2.8% ) Precedex . The U.S. market is ~$156M. Mylan has 295 ANDAs pending FDA approval representing ~$105B

    8. Why Tax Inversions Won't Go Away

      Headlines

      Wed, 13 Aug 2014

      PRGO ) acquiring Elan Pharmaceuticals of Ireland Mylan Laboratories (NASDAQ: MYL ) acquiring an Abbott Laboratories (NYSE: ABT ) subsidiary to move to the Netherlands Mylan getting rejected by Meda (MEDAA) Complete Story

    9. New Morningstar Analyst Report for Mallinckrodt PLC

      Stock Reports

      Wed, 13 Aug 2014

      While we believe an acquisition is possible, we would caution against investors speculating on a takeover, given that Mylan /Abbott and Salix/Cosmo have recently shown the market ways to drastically lower tax rates without acquiring an Irish

    10. The Long Case For Mylan

      Headlines

      Mon, 11 Aug 2014

      By MYL ) by downgrading price targets for the year ..... of 20% compared to their current 35%. Mylan remains deal hungry and has the balance sheet ..... is a buyers market. Company Description Mylan is one of the world's largest pharmaceutical

    « Prev12345Next »
    Content Partners